Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I

Lalitha R. Belur, Megan Romero, Junggu Lee, Kelly M. Podetz-Pedersen, Zhenhong Nan, Maureen S. Riedl, Lucy Vulchanova, Kelley F. Kitto, Carolyn A. Fairbanks, Karen F. Kozarsky, Paul J. Orchard, William H. Frey, Walter C. Low, R. Scott McIvor

Research output: Contribution to journalArticlepeer-review

Abstract

Mucopolysaccharidosis type I (MPS I) is an inherited metabolic disorder caused by deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA). The two current treatments [hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT)], are insufficiently effective in addressing neurologic disease, in part due to the inability of lysosomal enzyme to cross the blood brain barrier. With a goal to more effectively treat neurologic disease, we have investigated the effectiveness of AAV-mediated IDUA gene delivery to the brain using several different routes of administration. Animals were treated by either direct intracerebroventricular (ICV) injection, by intrathecal (IT) infusion into the cerebrospinal fluid, or by intranasal (IN) instillation of AAV9-IDUA vector. AAV9-IDUA was administered to IDUA-deficient mice that were either immunosuppressed with cyclophosphamide (CP), or immunotolerized at birth by weekly injections of human iduronidase. In animals treated by ICV or IT administration, levels of IDUA enzyme ranged from 3- to 1000-fold that of wild type levels in all parts of the microdissected brain. In animals administered vector intranasally, enzyme levels were 100-fold that of wild type in the olfactory bulb, but enzyme expression was close to wild type levels in other parts of the brain. Glycosaminoglycan levels were reduced to normal in ICV and IT treated mice, and in IN treated mice they were normalized in the olfactory bulb, or reduced in other parts of the brain. Immunohistochemical analysis showed extensive IDUA expression in all parts of the brain of ICV treated mice, while IT treated animals showed transduction that was primarily restricted to the hind brain with some sporadic labeling seen in the mid- and fore brain. At 6 months of age, animals were tested for spatial navigation, memory, and neurocognitive function in the Barnes maze; all treated animals were indistinguishable from normal heterozygous control animals, while untreated IDUA deficient animals exhibited significant learning and spatial navigation deficits. We conclude that IT and IN routes are acceptable and alternate routes of administration, respectively, of AAV vector delivery to the brain with effective IDUA expression, while all three routes of administration prevent the emergence of neurocognitive deficiency in a mouse MPS I model.

Original languageEnglish (US)
Article number618360
JournalFrontiers in Molecular Neuroscience
Volume14
DOIs
StatePublished - May 10 2021

Bibliographical note

Funding Information:
This study was funded by the NIH grant P01 HD032652 to the University of Minnesota and NIH grant R41 DK094538 to REGENXBIO Inc. Behavioral studies were performed in the Mouse Behavior Core at the University of Minnesota (supported by NIH grant NS062158).

Funding Information:
We thank core director Dr. Benneyworth for assistance with the Barnes maze testing. This study was previously presented as a poster at an American Society of Gene and Cell Therapy conference, and has been published in abstract form in conference proceedings. Funding. This study was funded by the NIH grant P01 HD032652 to the University of Minnesota and NIH grant R41 DK094538 to REGENXBIO Inc. Behavioral studies were performed in the Mouse Behavior Core at the University of Minnesota (supported by NIH grant NS062158).

Publisher Copyright:
© Copyright © 2021 Belur, Romero, Lee, Podetz-Pedersen, Nan, Riedl, Vulchanova, Kitto, Fairbanks, Kozarsky, Orchard, Frey, Low and McIvor.

Keywords

  • AAV9
  • IDUA
  • MPS I
  • gene therapy
  • intracerebroventricular administration
  • intranasal infusion
  • intrathecal injection

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I'. Together they form a unique fingerprint.

Cite this